The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome

Konrad Lewandowski; Magdalena Kaniewska; Katarzyna Karłowicz; Mariusz Rosołowski; Grażyna Rydzewska

doi:10.5114/pg.2021.112681

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2022
vol. 17

Send email

Copy url:

abstract:

Original paper

The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome

Konrad Lewandowski

¹

,

Magdalena Kaniewska

¹

,

Katarzyna Karłowicz

¹

,

Mariusz Rosołowski

^{2, 3}

,

Grażyna Rydzewska

^{1, 4}

Clinical Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, Central Clinical Hospital of the Ministry of the Inferior and Administration, Warsaw, Poland
Department of Internal Medicine and Hypertension, Medical University of Bialystok, Bialystok, Poland
Department of Hypertension, Gastroenterology and Internal Medicine, Medical University of Bialystok Clinical Hospital, Bialystok, Poland
Collegium Medicum, Jan Kochanowski University, Kielce, Poland

Gastroenterology Rev 2022; 17 (1): 28–34

DOI: https://doi.org/10.5114/pg.2021.112681

Online publish date: 2022/01/18

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Lewandowski K, Kaniewska M, Karłowicz K, Rosołowski M, Rydzewska G. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Gastroenterology Review/Przegląd Gastroenterologiczny. 2022;17(1):28-34. doi:10.5114/pg.2021.112681.

APA

Lewandowski, K., Kaniewska, M., Karłowicz, K., Rosołowski, M.,  & Rydzewska, G. (2022). The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Gastroenterology Review/Przegląd Gastroenterologiczny, 17(1), 28-34. https://doi.org/10.5114/pg.2021.112681

Chicago

Lewandowski, Konrad, Magdalena Kaniewska, Katarzyna Karłowicz, Mariusz Rosołowski,  and Grażyna Rydzewska. 2022. "The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome". Gastroenterology Review/Przegląd Gastroenterologiczny 17 (1): 28-34. doi:10.5114/pg.2021.112681.

Harvard

Lewandowski, K., Kaniewska, M., Karłowicz, K., Rosołowski, M.,  and Rydzewska, G. (2022). The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Gastroenterology Review/Przegląd Gastroenterologiczny, 17(1), pp.28-34. https://doi.org/10.5114/pg.2021.112681

MLA

Lewandowski, Konrad et al. "The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 17, no. 1, 2022, pp. 28-34. doi:10.5114/pg.2021.112681.

Vancouver

Lewandowski K, Kaniewska M, Karłowicz K, Rosołowski M, Rydzewska G. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Gastroenterology Review/Przegląd Gastroenterologiczny. 2022;17(1):28-34. doi:10.5114/pg.2021.112681.

PlumX metrics:

Introduction
The aim of the study was to assess the effectiveness of a patented preparation of sodium butyrate in the triglyceride matrix at reducing clinical symptoms and improving quality of life in patients with irritable bowel syndrome (IBS).

Material and methods
In this prospective multicenter clinical trial, we observed a total of 3000 non-hospitalized patients with confirmed IBS who were treated with sodium butyrate in a triglyceride matrix at a dosage of 150 mg twice a day for 12 weeks. The primary outcome was to evaluate the efficacy of sodium butyrate at reducing the severity of clinical symptoms and improving quality of life in patients with IBS.

Results
A total of 2990 complete surveys were collected. A statistically significant improvement in severity of abdominal pain was noticed (p < 0.001). Moreover, flatulence, diarrhea, constipation, urgent pressure for bowel movements, nausea, and vomiting decreased significantly (p < 0.001). Most of the respondents (93.90%) declared that they would continue the therapy and 88.9% would recommend using sodium butyrate to other IBS patients.

Conclusions
Sodium butyrate in the triglyceride matrix, as a postbiotic substance, may be effective in relieving the symptoms of IBS by modifying the intestinal microbiota.

keywords:

The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome

Konrad Lewandowski 1 , Magdalena Kaniewska 1 , Katarzyna Karłowicz 1 , Mariusz Rosołowski 2, 3 , Grażyna Rydzewska 1, 4

irritable bowel syndrome, symptoms, overweight, sodium butyrate

Konrad Lewandowski

¹

,

Magdalena Kaniewska

¹

,

Katarzyna Karłowicz

¹

,

Mariusz Rosołowski

^{2, 3}

,

Grażyna Rydzewska

^{1, 4}